Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGFTAI)

• Drug Name: SHR0534 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMGFTAI

Molecule-Related Drug Atlas

Drug(s) Targeting Free fatty acid receptor 1 (GPR40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TAK-875	DMIM5AP	Type-2 diabetes	5A11	Phase 3	[3]
Fasiglifam hemihydrate	DMTGYSO	Type-2 diabetes	5A11	Phase 3	[4]
PBI-4050	DMPXK27	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[5]
P-1736	DMEYQPN	Diabetic complication	5A2Y	Phase 2	[6]
JTT-851	DMED5J6	Type-2 diabetes	5A11	Phase 2	[7]
LY-2881835	DM5EXJV	Type-2 diabetes	5A11	Phase 1	[7]
P11187	DMXZOI0	Type-2 diabetes	5A11	Phase 1	[7]
CPL207-280CA	DMFMGZR	Type 2 diabetes	5A11	Phase 1	[2]
LY2922470	DMGLTE2	Type 2 diabetes	5A11	Phase 1	[8]
CNX-011-67	DM1H8D6	Type 2 diabetes	5A11	Preclinical	[9]

Drug(s) Targeting Inflammation-related GPCR EX33 (GPR84)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PBI-4050	DMPXK27	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[5]
3-hydroxy capric acid	DMC70P1	Discovery agent	N.A.	Investigative	[10]
2-hydroxy capric acid	DMJAN52	Discovery agent	N.A.	Investigative	[10]
6-n-octylaminouracil	DMXJFCQ	Discovery agent	N.A.	Investigative	[10]
3-hydroxylauric acid	DMNMB6V	Discovery agent	N.A.	Investigative	[10]
2-hydroxylauric acid	DMCNW3M	Discovery agent	N.A.	Investigative	[10]
undecanoic acid	DMFOIPL	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 1 (GPR40)	TTB8FUC	FFAR1_HUMAN	Agonist	[2]
Inflammation-related GPCR EX33 (GPR84)	TTG0MQD	GPR84_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT03006159) A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients. U.S. National Institutes of Health.
• [2] Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
• [3] Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
• [4] A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
• [5] Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
• [6] Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
• [7] Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
• [8] The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.
• [9] CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19.
• [10] Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
• [11] Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006 Nov 10;281(45):34457-64.